Clinical Trial Update: Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a high-dose sublingual grass pollen preparation shows efficacy and safety data in allergic rhinitis and allergic conjunctivitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Allergic Rhinitis

Drugs mentioned

• Grass pollen sublingual immunotherapy (high-dose) (grass pollen extract for sublingual immunotherapy)

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: Allergy, Rhinitis | Phase 3 | Status: COMPLETED